We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics
ALDX

89 hedge funds and large institutions have $197M invested in Aldeyra Therapeutics in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 32 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more capital invested

Capital invested by funds: $147M → $197M (+$50.5M)

0.01% more ownership

Funds ownership: 63.38% → 63.39% (+0.01%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less funds holding

Funds holding: 95 → 89 (-6)

30% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 20

31% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 32

37% less call options, than puts

Call options by funds: $1.6M | Put options by funds: $2.55M

Holders
89
Holders Change
-6
Holders Change %
-6.32%
% of All Funds
1.53%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
22
Reduced
32
Closed
20
Calls
$1.6M
Puts
$2.55M
Net Calls
-$945K
Net Calls Change
-$2.46M

Top Buyers

1
PA
Perceptive Advisors
New York
+$8.68M
2
TCM
Tang Capital Management
California
+$4.2M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.58M
4
Verition Fund Management
Verition Fund Management
Connecticut
+$3.01M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.26M

Top Sellers

1
Goldman Sachs
Goldman Sachs
New York
-$5.98M
2
PM
Prosight Management
Texas
-$4.65M
3
UBS Group
UBS Group
Switzerland
-$4.41M
4
Citadel Advisors
Citadel Advisors
Florida
-$3.92M
5
Millennium Management
Millennium Management
New York
-$3.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
76
Citigroup
New York
$27K -$2.17M -361,218 -99%
Royal Bank of Canada
77
Royal Bank of Canada
Ontario, Canada
$12K +$7.73K +1,289 +134%
SC
78
Stephens Consulting
Michigan
$5.34K – – –
TC
79
Truvestments Capital
Florida
$5K – – –
JG
80
Jefferies Group
New York
$4.31K +$4.84K +807 New
LC
81
Lindbrook Capital
California
$4K – – –
BNP Paribas Financial Markets
82
BNP Paribas Financial Markets
France
$3.45K -$9.32K -1,554 -71%
PA
83
PSI Advisors
Florida
$3K – – –
WAM
84
Worth Asset Management
Texas
$3K – – –
HWM
85
HighMark Wealth Management
Minnesota
$1K -$3.66K -610 -80%
PNC Financial Services Group
86
PNC Financial Services Group
Pennsylvania
$1K +$1.48K +246 New
IC
87
Ikarian Capital
Texas
– -$1.5M -375,000 Closed
E
88
Ergoteles
New York
– -$952K -238,500 Closed
Bank of Montreal
89
Bank of Montreal
Ontario, Canada
– -$324 -80,700 Closed
CANY
90
Caxton Associates (New York)
New York
– -$231K -57,860 Closed
BFM
91
Boothbay Fund Management
New York
– -$224K -56,082 Closed
PAG
92
Private Advisor Group
New Jersey
– -$196K -49,165 Closed
AQR Capital Management
93
AQR Capital Management
Connecticut
– -$163K -40,954 Closed
Simplex Trading
94
Simplex Trading
Illinois
– -$187K -31,249 Closed
XT
95
XTX Topco
Cayman Islands
– -$87K -21,841 Closed
SW
96
SlateStone Wealth
Florida
– -$48K -11,964 Closed
Squarepoint
97
Squarepoint
New York
– -$44K -10,964 Closed
Wolverine Trading
98
Wolverine Trading
Illinois
– -$61.8K -10,309 Closed
PI
99
PEAK6 Investments
Illinois
– -$46.1K -5,500 Closed
QT
100
Quantbot Technologies
New York
– -$18K -4,668 Closed
1 2 3
4
5

ALDX Hedge Fund Activity: Q3 2022 in Review

89 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2022, worth a combined $197M — up 34% from $147M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ALDX and 14 opened new positions — a net loss of 6 holders — while 32 trimmed existing stakes and 22 added.

The largest buyer was Perceptive Advisors, adding an estimated $8.68M. The largest seller was Goldman Sachs, cutting an estimated $5.98M.

  • 89 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2022, down from 95 in Q2 2022.
  • Funds reported $197M of Aldeyra Therapeutics stock for Q3 2022, up 34% quarter-over-quarter.
  • 14 funds opened new Aldeyra Therapeutics positions in Q3 2022 and 20 closed out, a net change of -6 holders.
  • The largest Aldeyra Therapeutics buyer in Q3 2022 was Perceptive Advisors, an estimated $8.68M added.
  • The largest Aldeyra Therapeutics seller in Q3 2022 was Goldman Sachs, an estimated $5.98M sold.

Based on aggregated 13F filings for Q3 2022.